Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zymar Clear all

Conditions: Healthy
Interventions: 1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution, 0.3% gatifloxacin ophthalmic solution; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Ophthalmic Surgery
Interventions: Zymar; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Bacterial Conjunctivitis
Interventions: Gatifloxacin 0.5% eye drops, placebo eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 1 Year and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Gretna, Louisiana

Conditions: Bacterial Conjunctivitis
Interventions: Gatifloxacin 0.5% eye drops, placebo eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 1 Year and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Downey, California

Conditions: Cataract Extraction
Interventions: Besifloxacin hydrochloride, moxifloxacin hydrochloride, gatifloxacin; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Rockville Centre, New York

Conditions: Osteomyelitis
Interventions: oral antibiotics, intravenous antibiotics; Drug · Procedure
Lead sponsor: Julio Ramirez; Other
Eligibility: 18 Years to 100 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Macula Thickening
Interventions: Prednisolone Acetate, Ketorolac 0.4%, Gatifloxacin 0.3%; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 50 Years and older
U.S. locations: 1
States / cities: Rockville Centre, New York

Conditions: Bacterial Conjunctivitis
Interventions: Besivance, Gatifloxacin; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 1 Day to 31 Days
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Bacterial Conjunctivitis
Interventions: gatifloxacin, moxifloxacin 0.5% eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: Up to 31 Days
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting
Interventions: Oral Fluoroquinolones (FQ), Other Antibiotics, Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: Not listed
Enrollment: 117,911 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Intravitreous, Injections
Interventions: gatifloxacin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cataract
Interventions: intraocular triamcinolone and gatifloxicin; Drug
Lead sponsor: Dean Health System; Other
Eligibility: 40 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baraboo, Wisconsin

Conditions: Eye Infection, Infection
Interventions: Moxifloxacin ophthalmic solution 0.5%, Gatifloxacin ophthalmic solution 0.3%; Drug
Lead sponsor: Ophthalmic Consultants of Boston; Other
Eligibility: 25 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tuberculosis
Interventions: Gatifloxacin, Isoniazid, Levofloxacin, Linezolid, Moxifloxacin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cataract Surgery
Interventions: Gatifloxacin, Ketorolac LS, Pred Forte, Moxifloxacin, Nepafenac, EconoPred Plus; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Anti-biotic Resistance
Interventions: moxifloxacin 0.5% HCI ophthalmic solution, gatifloxacin ophthalmic solution 0.3%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 50 Years and older
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: Gatifloxacin, Moxifloxacin, Besifloxacin; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acute Bacterial Corneal Ulcers, Bacterial Keratitis
Interventions: Gatifloxacin 0.3% ophthalmic solution, Ciprofloxacin 0.3% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 8 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Epithelium, Corneal
Interventions: Moxifloxacin, Gatifloxacin; Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Corneal Ulcers
Interventions: Besivance 0.6% Ophthalmic Suspension, Zymaxid 0.5% Ophthalmic Solution, Vigamox 0.5% Ophthalmic Solution; Drug
Lead sponsor: Cornea Consultants Of Nashville; Other
Eligibility: 18 Years to 90 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cataract
Interventions: Pred-Gati-Brom, Prednisolone acetate 1% ophthalmic suspension, Gatifloxacin Ophthalmic, Bromfenac 0.075% Oph Solution; Drug
Lead sponsor: Carolina Eyecare Physicians, LLC; Other
Eligibility: 50 Years to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Mt. Pleasant, South Carolina

Conditions: Age-related Macular Degeneration
Interventions: Conjunctival and nasopharyngeal bacteria cultures; Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

One Hour Preoperative Gatifloxacin

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

Patients Response to Early Switch To Oral:Osteomyelitis Study

Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation

Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

Topical Antibiotics and Intravitreous Injections

Intraocular Steroid After Cataract Surgery Study

Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose

Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis

Therapeutic Variables in Cataract Surgery

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers

Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen

Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics